Mahesh Kumar Posa

Prof. Mahesh Kumar Posa


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2026 in Research Square
Verified
Preprint
Open access
PDF file
AYAnup Lal Yadav
Anup Lal Yadav
SSSonal Solanki
Sonal Solanki
NSNikunj Solanki
Nikunj Solanki
VPVishin Ashish Patil
Vishin Ashish Patil
SSSreenath Sriram
Sreenath Sriram
JPJayashree Prasad
Jayashree Prasad
A decision-centric workflow was developed to link a QbD-defined design space with interpretable surrogate modeling for rapid selection of ultrasound-triggered doxorubicin-loaded chitosan microbubbles. A 15-run Box–Behnken design spanning chitosan, palmitic acid, and Pluronic F68 was used to quantify three critical quality attributes (CQAs)—mean size, encapsulation efficiency (EE), and burst release at 40 s (Burst40)—and to train response-specific surrogates evaluated by leave-one-out cross-validation (LOOCV). The DoE produced a broad performance envelope (size 2.35–4.85 µm; EE 60–82%; Burst40 55.6–95%) with clear composition-driven trade-offs, notably between EE and acoustic responsiveness. A regularized polynomial surrogate (PolyRidge) provided strong LOOCV performance for size (R²=0.885; RMSE = 0.264 µm) and EE (R²=0.871; RMSE = 2.18%), whereas Burst40 was only moderately predictable (R²=0.501; RMSE = 8.61%), consistent with threshold-like cavitation and microstructure sensitivity. Digital screening with multi-objective desirability and explainability (SHAP, permutation importance, partial dependence, LIME) shortlisted manufacturable candidates; experimental validation showed QbD/RSM was better calibrated for absolute size and EE, while both modeling approaches remained similarly limited for Burst40. Importantly, shortlisted formulations preserved suppressed baseline release and pronounced ultrasound-enhanced release, yielding trigger-dependent cytotoxicity and increased apoptotic commitment in MCF-7 cells.

26 March 2026 in EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES
Verified
Journal Article
Closed access
STSAMPAT SINGH TANWAR
SAMPAT SINGH TANWAR
Mahesh Kumar PosaMahesh Kumar Posa
Mahesh Kumar Posa
RKRavi Kumar Kota
Ravi Kumar Kota
VIV.T. Iswariya
V.T. Iswariya
PMP. Moulika
P. Moulika
SSSeema Sharma
Seema Sharma
Nanotechnology has transformed contemporary pharmaceuticals by providing nanoscale materials that enable precise drug delivery, controlled release, and targeted therapeutic applications. Silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) have emerged as exceptionally versatile agents owing to their adjustable size, shape, surface characteristics, and biocompatibility. This review offers an extensive examination of their pharmaceutical potential, emphasizing synthesis techniques namely, chemical, biological green, and physical methods and their impact on nanoparticle morphology, stability, and functionalization. Silver nanoparticles (AgNPs) exhibit significant antimicrobial efficacy and are extensively utilized in wound healing and infection management, whereas gold nanoparticles (AuNPs) are favoured in oncology, gene delivery, photothermal therapy, and diagnostics owing to their inertness and optical characteristics. Surface engineering techniques, including PEGylation and ligand conjugation (e.g., antibodies, aptamers, folic acid), enhance systemic circulation, targeting precision, and therapeutic efficacy. The review examines drug loading methodologies utilizing covalent and non-covalent interactions, as well as hybrid delivery systems such as liposomes and hydrogels, which facilitate improved entrapment efficiency and targeted delivery. Mechanistic understanding of drug release through diffusion, swelling, erosion, and degradation is underpinned by mathematical models such as Higuchi, Korsmeyer–Peppas, and zero-order kinetics. Recent innovations, including stimuli-responsive systems, microneedle patches, and AI-assisted formulation optimization are also examined. Notwithstanding substantial advancements, critical obstacles persist in large-scale production, nanotoxicity assessment, and regulatory authorization. Nonetheless, AgNPs and AuNPs signify a transformative advancement in pharmaceutical development, possessing the capacity to propel the forthcoming generation of personalized, adaptive, and intelligent drug delivery systems.